Abstract
OBJECTIVE To test whether a practice-level intervention to promote the systematic identification, treatment, and follow-up of smokers (the OttawaModel for Smoking Cessation [OMSC]) would improve long-Term abstinence rates among smoker-patients with type 2 diabetes or prediabetes receiving care from diabetes education programs in Ontario, Canada. RESEARCH DESIGN AND METHODS The Tobacco Intervention in Diabetes Education study was a matched-pair, clusterrandomized clinical trial.Within each pair, siteswere randomly allocated to either an OMSC intervention (n = 7) or a wait-list control (WLC) condition (n = 7). Diabetes education programs in the OMSC group introduced standardized processes to identify smokers and routinely provided smoking cessation interventions and follow-up. Smokers in the OMSC group received counseling, a discount card to partially cover the cost of smoking cessation medication, and follow-up telephone calls over a 6-month period. Diabetes education programs in the WLC condition were offered the OMSC intervention after a 1-year waiting period. Smokers in the WLC group received usual care for smoking cessation fromtheir diabetes educator. The primary end point was carbon monoxide (CO)-confirmed 7-day point prevalence abstinence from smoking at 6-month follow-up. RESULTS A total of 313 smokers (OMSC group n = 199, WLC group n = 114) with diabetes or prediabetes were enrolled. The CO-confirmed abstinence rate at 6 months was 11.1% in the OMSC group versus 2.6% in the WLC group (odds ratio 3.73 [95% CI 1.20, 11.58]; P = 0.02). CONCLUSIONS Implementation of the OMSC in diabetes education programs resulted in clinically and statistically significant improvements in long-Term abstinence among smokers with diabetes or prediabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 406-412 |
| Number of pages | 7 |
| Journal | Diabetes Care |
| Volume | 41 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2018 |
Bibliographical note
Funding Information:Funding. Planning, design, and preparation of the funding proposal for the TIDE study was completed as part of a Canadian Institutes of Health Research Meetings, Planning and Dissemination grant (application #256992). Pfizer funded TIDE, an investigator-initiated trial, with a Global Research Award for Nicotine Dependence. Pfizer played no roleinthedesign,conduct,analysis,interpretation of data, or reporting of the TIDE trial. Duality of Interest. The OMSC is a trademark of the University of Ottawa Heart Institute, which employs several of the authors. R.D.R., A.Gu., P.O., and A.L.P. have received honoraria from Pfizer for providing continuing medical education on smoking cessation. R.D.R and A.L.P. have received honoraria from Johnson & Johnson for providing continuing medical education on smoking cessation. No other potential conflicts of interest relevant to this article were reported. Author Contributions. R.D.R. designed the study, oversaw the data collection, conducted the statistical analysis, and wrote the manuscript. J.M., D.Ar., C.B., A.Gu., K.-A.M., P.O., S.P., H.T.,G.A.W.,andA.L.P.designedthestudy.E.W., A.Ge.,D.Ai.,andJ.-A.G.collecteddata.A.G.L.and G.A.W. conducted statistical analyses. All authors reviewed andeditedthemanuscriptandapproved its final form. R.D.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Publisher Copyright:
© 2017 by The American Diabetes Association.
ASJC Scopus Subject Areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialised Nursing
PubMed: MeSH publication types
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
